NCT06823427View on ClinicalTrials.gov

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 17, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma RecurrentUrothelial Carcinoma of the Renal Pelvis and Ureter
Interventions
DRUG

9MW2821

a nectin-4 ADC with MMAE payload

DRUG

Toripalimab (JS001 )

anit-PD-1 antibody

Trial Locations (2)

210000

RECRUITING

Nanjing Drum Tower Hospital, Nanjing

410013

RECRUITING

Hunan Tumor Hospital, Changsha

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY